ClinicaliQ Trial Snapshot
- A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries — Recruiting • Cardiology / Cardiovascular • NCT07251933.
- What is being tested: Lanadelumab, a monoclonal antibody targeting plasma kallikrein, is being evaluated as a preventative treatment for hereditary angioedema (HAE) in the paediatric population across multiple countries.
- Patient eligibility overview: The trial enrolls children with confirmed HAE diagnosis; specific age ranges and disease severity criteria apply, with participants typically requiring documented recurrent angioedema episodes despite current management.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
HAE is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels but does not cause itching or hives. HAE is classified based on the amount of a protein in the blood called C1 inhibitor (C1-INH): HAE with normal C1-INH levels and HAE with limited or insufficient C1-INH levels (C1-INH deficiency). This study will concentrate on children with HAE C1-INH deficiency who have received Takhzyro (Lanadelumab) as prophylactic…
Eligibility Snapshot
- :
- Participant is aged 2 to less than (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.